U.K. agency suggests restriction on use of drug-eluting stents

09/24/2008 | FDAnews

The use of drug-eluting stents should be limited to coronary-artery disease patients who would likely require future interventions if they received a conventional bare-metal stent instead, according to a final guidance from the U.K.'s National Institute for Health and Clinical Excellence. NICE's final guidance offers data on specific drug-coated stents and their individual prices.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY